- Is Pharmacogenomics Research Network a tax-exempt 501(c)(3)?
- Yes. Pharmacogenomics Research Network is recognised by the IRS as a 501(c)(3) organisation (EIN 84-4444433). The IRS recognised Pharmacogenomics Research Network as tax-exempt in April 2020.
- What is Pharmacogenomics Research Network's EIN?
- Pharmacogenomics Research Network's Employer Identification Number (EIN) is 84-4444433. The EIN was assigned by the IRS in April 2020. Donors and grantmakers use the EIN to verify tax-exempt status with the IRS.
- What does Pharmacogenomics Research Network do?
- Conducted over 20 webinars for doctors and clinicians; conducted annual meeting for members, researchers, scientists and academics in Missoula MT on September 10-12, 2025; promoted and funded laboratory research in Pharmacogenomics
- Where is Pharmacogenomics Research Network located?
- Pharmacogenomics Research Network is located at 10865 Hazelhurst Drive 26427, Houston, TX, 77043.
- When was Pharmacogenomics Research Network founded or recognised by the IRS?
- Pharmacogenomics Research Network was recognised by the IRS as a tax-exempt organisation in April 2020. The IRS ruling date is the earliest authoritative date available for most US nonprofits.
- What is Pharmacogenomics Research Network's annual revenue?
- On its most recent Form 990 (fiscal year 2025), Pharmacogenomics Research Network reported $255K in total revenue and $209K in total expenses.
- Has Pharmacogenomics Research Network been auto-revoked by the IRS?
- No. Pharmacogenomics Research Network (EIN 84-4444433) does not appear on the IRS Auto-Revocation List. Givalgo Discover cross-references the IRS Auto-Revocation List on every profile load; if status changes, this page reflects it.
- Is Pharmacogenomics Research Network listed in IRS Publication 78?
- Yes. Pharmacogenomics Research Network is listed in IRS Publication 78 as an organisation eligible to receive tax-deductible charitable contributions. Pub 78 status is the canonical IRS signal that donations to an org are deductible.
